1
|
Meibom D, Wasnaire P, Beyer K, Broehl A, Cancho-Grande Y, Elowe N, Henninger K, Johannes S, Jungmann N, Krainz T, Lindner N, Maassen S, MacDonald B, Menshykau D, Mittendorf J, Sanchez G, Schaefer M, Stefan E, Torge A, Xing Y, Zubov D. BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor. J Med Chem 2024; 67:2907-2940. [PMID: 38348661 PMCID: PMC10895658 DOI: 10.1021/acs.jmedchem.3c02036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 12/20/2023] [Accepted: 12/22/2023] [Indexed: 02/23/2024]
Abstract
The matrix metalloprotease ADAMTS7 has been identified by multiple genome-wide association studies as being involved in the development of coronary artery disease. Subsequent research revealed the proteolytic function of the enzyme to be relevant for atherogenesis and restenosis after vessel injury. Based on a publicly known dual ADAMTS4/ADAMTS5 inhibitor, we have in silico designed an ADAMTS7 inhibitor of the catalytic domain, which served as a starting point for an optimization campaign. Initially our inhibitors suffered from low selectivity vs MMP12. An X-ray cocrystal structure inspired us to exploit amino acid differences in the binding site of MMP12 and ADAMTS7 to improve selectivity. Further optimization composed of employing 5-membered heteroaromatic groups as hydantoin substituents to become more potent on ADAMTS7. Finally, fine-tuning of DMPK properties yielded BAY-9835, the first orally bioavailable ADAMTS7 inhibitor. Further optimization to improve selectivity vs ADAMTS12 seems possible, and a respective starting point could be identified.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Eric Stefan
- Broad
Institute, 02142 Cambridge, United States
| | | | - Yi Xing
- Broad
Institute, 02142 Cambridge, United States
| | | |
Collapse
|
2
|
Roehrig S, Ackerstaff J, Jiménez Núñez E, Teller H, Ellerbrock P, Meier K, Heitmeier S, Tersteegen A, Stampfuss J, Lang D, Schlemmer KH, Schaefer M, Gericke KM, Kinzel T, Meibom D, Schmidt M, Gerdes C, Follmann M, Hillisch A. Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders. J Med Chem 2023; 66:12203-12224. [PMID: 37669040 PMCID: PMC10510402 DOI: 10.1021/acs.jmedchem.3c00795] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Indexed: 09/06/2023]
Abstract
Activated coagulation factor XI (FXIa) is a highly attractive antithrombotic target as it contributes to the development and progression of thrombosis but is thought to play only a minor role in hemostasis so that its inhibition may allow for decoupling of antithrombotic efficacy and bleeding time prolongation. Herein, we report our major efforts to identify an orally bioavailable, reversible FXIa inhibitor. Using a protein structure-based de novo design approach, we identified a novel micromolar hit with attractive physicochemical properties. During lead modification, a critical problem was balancing potency and absorption by focusing on the most important interactions of the lead series with FXIa while simultaneously seeking to improve metabolic stability and the cytochrome P450 interaction profile. In clinical trials, the resulting compound from our extensive research program, asundexian (BAY 2433334), proved to possess the desired DMPK properties for once-daily oral dosing, and even more importantly, the initial pharmacological hypothesis was confirmed.
Collapse
Affiliation(s)
- Susanne Roehrig
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | | | | | | | | | | | - Stefan Heitmeier
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | - Adrian Tersteegen
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | - Jan Stampfuss
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | - Dieter Lang
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | | | | | - Kersten M. Gericke
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | | | - Daniel Meibom
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | - Martina Schmidt
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | - Christoph Gerdes
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | - Markus Follmann
- Pharmaceuticals, Research
and Development, Bayer AG, 42133 Wuppertal, Germany
| | | |
Collapse
|
3
|
Meibom D, Meyer J, von Buehler CJ, Collins KD, Maassen S, Gericke KM, Hüser J, Mittendorf J, Ortega Hernandez N, Schamberger J, Stampfuss J, Straub A, Torge A, Witowski N, Wunder F. BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α 2B Antagonist. J Med Chem 2023; 66:4659-4670. [PMID: 36932954 PMCID: PMC10108358 DOI: 10.1021/acs.jmedchem.2c01690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
Abstract
After acute myocardial infarction, early reperfusion is the most effective strategy for reducing cardiac damage and improving clinical outcome. However, restoring blood flow to the ischemic myocardium can paradoxically induce injury by itself (reperfusion injury), with microvascular dysfunction being one contributing factor. α2B adrenergic receptors have been hypothesized to be involved in this process. To assess α2B-related pharmacology, we identified a novel α2B antagonist by HTS. The HTS hit showed limited α2A selectivity as well as low solubility and was optimized toward BAY-6096, a potent, selective, and highly water-soluble α2B antagonist. Key aspects of the optimization were the introduction of a permanently charged pyridinium moiety to achieve very good aqueous solubility and the inversion of an amide to prevent genotoxicity. BAY-6096 dose-dependently reduced blood pressure increases in rats induced by an α2B agonist, demonstrating the role of α2B receptors in vascular constriction in rats.
Collapse
|
4
|
Poongavanam V, Kölling F, Giese A, Göller AH, Lehmann L, Meibom D, Kihlberg J. Predictive Modeling of PROTAC Cell Permeability with Machine Learning. ACS Omega 2023; 8:5901-5916. [PMID: 36816707 PMCID: PMC9933238 DOI: 10.1021/acsomega.2c07717] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2022] [Accepted: 01/19/2023] [Indexed: 06/18/2023]
Abstract
Approaches for predicting proteolysis targeting chimera (PROTAC) cell permeability are of major interest to reduce resource-demanding synthesis and testing of low-permeable PROTACs. We report a comprehensive investigation of the scope and limitations of machine learning-based binary classification models developed using 17 simple descriptors for large and structurally diverse sets of cereblon (CRBN) and von Hippel-Lindau (VHL) PROTACs. For the VHL PROTAC set, kappa nearest neighbor and random forest models performed best and predicted the permeability of a blinded test set with >80% accuracy (k ≥ 0.57). Models retrained by combining the original training and the blinded test set performed equally well for a second blinded VHL set. However, models for CRBN PROTACs were less successful, mainly due to the imbalanced nature of the CRBN datasets. All descriptors contributed to the models, but size and lipophilicity were the most important. We conclude that properly trained machine learning models can be integrated as effective filters in the PROTAC design process.
Collapse
Affiliation(s)
| | - Florian Kölling
- Computational
Molecular Design, Bayer AG, 42096Wuppertal, Germany
| | - Anja Giese
- Drug
Discovery Sciences, Bayer AG, 13342Berlin, Germany
| | | | - Lutz Lehmann
- Drug
Discovery Sciences, Bayer AG, 42113Wuppertal, Germany
| | - Daniel Meibom
- Drug
Discovery Sciences, Bayer AG, 42113Wuppertal, Germany
| | - Jan Kihlberg
- Department
of Chemistry-BMC, Box 576, Uppsala University, 75123Uppsala, Sweden
| |
Collapse
|
5
|
Meibom D, Micus S, Andreevski AL, Anlauf S, Bogner P, von Buehler CJ, Dieskau AP, Dreher J, Eitner F, Fliegner D, Follmann M, Gericke KM, Maassen S, Meyer J, Schlemmer KH, Steuber H, Tersteegen A, Wunder F. BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor. J Med Chem 2022; 65:16420-16431. [PMID: 36475653 PMCID: PMC9791655 DOI: 10.1021/acs.jmedchem.2c01267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Despite advances in the treatment of heart failure in recent years, options for patients are still limited and the disease is associated with considerable morbidity and mortality. Modulating cyclic guanosine monophosphate levels within the natriuretic peptide signaling pathway by inhibiting PDE9A has been associated with beneficial effects in preclinical heart failure models. We herein report the identification of BAY-7081, a potent, selective, and orally bioavailable PDE9A inhibitor with very good aqueous solubility starting from a high-throughput screening hit. Key aspect of the optimization was a switch in metabolism of our lead structures from glucuronidation to oxidation. The switch proved being essential for the identification of compounds with improved pharmacokinetic profiles. By studying a tool compound in a transverse aortic constriction mouse model, we were able to substantiate the relevance of PDE9A inhibition in heart diseases.
Collapse
|
6
|
Abstract
Proteolysis-targeting chimeras (PROTACs) must be cell permeable to reach their target proteins. This is challenging as the bivalent structure of PROTACs puts them in chemical space at, or beyond, the outer limits of oral druggable space. We used NMR spectroscopy and molecular dynamics (MD) simulations independently to gain insights into the origin of the differences in cell permeability displayed by three flexible cereblon PROTACs having closely related structures. Both methods revealed that the propensity of the PROTACs to adopt folded conformations with a low solvent-accessible 3D polar surface area in an apolar environment is correlated to high cell permeability. The chemical nature and the flexibility of the linker were essential for the PROTACs to populate folded conformations stabilized by intramolecular hydrogen bonds, π-π interactions, and van der Waals interactions. We conclude that MD simulations may be used for the prospective ranking of cell permeability in the design of cereblon PROTACs.
Collapse
Affiliation(s)
| | - Yoseph Atilaw
- Department of Chemistry─BMC, Uppsala University, Box 576, 75123 Uppsala, Sweden
| | - Stephan Siegel
- Drug Discovery Sciences, Bayer AG, 13342 Berlin, Germany
| | - Anja Giese
- Drug Discovery Sciences, Bayer AG, 13342 Berlin, Germany
| | - Lutz Lehmann
- Drug Discovery Sciences, Bayer AG, 42113 Wuppertal, Germany
| | - Daniel Meibom
- Drug Discovery Sciences, Bayer AG, 42113 Wuppertal, Germany
| | - Mate Erdelyi
- Department of Chemistry─BMC, Uppsala University, Box 576, 75123 Uppsala, Sweden
| | - Jan Kihlberg
- Department of Chemistry─BMC, Uppsala University, Box 576, 75123 Uppsala, Sweden
| |
Collapse
|
7
|
Atilaw Y, Poongavanam V, Svensson Nilsson C, Nguyen D, Giese A, Meibom D, Erdelyi M, Kihlberg J. Solution Conformations Shed Light on PROTAC Cell Permeability. ACS Med Chem Lett 2021; 12:107-114. [PMID: 33488971 PMCID: PMC7812666 DOI: 10.1021/acsmedchemlett.0c00556] [Citation(s) in RCA: 73] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Accepted: 12/18/2020] [Indexed: 12/18/2022] Open
Abstract
![]()
Proteolysis
targeting chimeras (PROTACs) induce intracellular degradation
of target proteins. Their bifunctional structure puts degraders in
a chemical space where ADME properties often complicate drug discovery.
Herein we provide the first structural insight into PROTAC cell permeability
obtained by NMR studies of a VHL-based PROTAC (1), which
is cell permeable despite having a high molecular weight and polarity
and a large number of rotatable bonds. We found that 1 populates elongated and polar conformations in solutions that mimic
extra- and intracellular compartments. Conformations were folded and
had a smaller polar surface area in chloroform, mimicking a cell membrane
interior. Formation of intramolecular and nonclassical hydrogen bonds,
π–π interactions, and shielding of amide groups
from solvent all facilitate cell permeability by minimization of size
and polarity. We conclude that molecular chameleonicity appears to
be of major importance for 1 to enter into target cells.
Collapse
Affiliation(s)
- Yoseph Atilaw
- Department of Chemistry - BMC, Uppsala University, SE-75123 Uppsala, Sweden
| | | | | | - Duy Nguyen
- Nuvisan Innovation Campus Berlin GmbH, Muellerstrasse 178, 13353 Berlin, Germany
| | - Anja Giese
- Drug Discovery Sciences, Bayer AG, 13342 Berlin, Germany
| | - Daniel Meibom
- Drug Discovery Sciences, Bayer AG, 42113 Wuppertal, Germany
| | - Mate Erdelyi
- Department of Chemistry - BMC, Uppsala University, SE-75123 Uppsala, Sweden
| | - Jan Kihlberg
- Department of Chemistry - BMC, Uppsala University, SE-75123 Uppsala, Sweden
| |
Collapse
|
8
|
Beck H, Thaler T, Meibom D, Meininghaus M, Jörißen H, Dietz L, Terjung C, Bairlein M, von Bühler CJ, Anlauf S, Fürstner C, Stellfeld T, Schneider D, Gericke KM, Buyck T, Lovis K, Münster U, Anlahr J, Kersten E, Levilain G, Marossek V, Kast R. Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). J Med Chem 2020; 63:11639-11662. [PMID: 32969660 DOI: 10.1021/acs.jmedchem.0c00834] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a rare and devastating chronic lung disease of unknown etiology. Despite the approved treatment options nintedanib and pirfenidone, the medical need for a safe and well-tolerated antifibrotic treatment of IPF remains high. The human prostaglandin F receptor (hFP-R) is widely expressed in the lung tissue and constitutes an attractive target for the treatment of fibrotic lung diseases. Herein, we present our research toward novel quinoline-based hFP-R antagonists, including synthesis and detailed structure-activity relationship (SAR). Starting from a high-throughput screening (HTS) hit of our corporate compound library, multiple parameter improvements-including increase of the relative oral bioavailability Frel from 3 to ≥100%-led to a highly potent and selective hFP-R antagonist with complete oral absorption from suspension. BAY-6672 (46) represents-to the best of our knowledge-the first reported FP-R antagonist to demonstrate in vivo efficacy in a preclinical animal model of lung fibrosis, thus paving the way for a new treatment option in IPF.
Collapse
Affiliation(s)
- Hartmut Beck
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Tobias Thaler
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Daniel Meibom
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Mark Meininghaus
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Hannah Jörißen
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Lisa Dietz
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Carsten Terjung
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Michaela Bairlein
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | | | - Sonja Anlauf
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Chantal Fürstner
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Timo Stellfeld
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dirk Schneider
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Kersten M Gericke
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Thomas Buyck
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Kai Lovis
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Uwe Münster
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Johanna Anlahr
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Elisabeth Kersten
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Guillaume Levilain
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Virginia Marossek
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| | - Raimund Kast
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany
| |
Collapse
|
9
|
Härter M, Kalthof B, Delbeck M, Lustig K, Gerisch M, Schulz S, Kast R, Meibom D, Lindner N. Novel non-xanthine antagonist of the A 2B adenosine receptor: From HTS hit to lead structure. Eur J Med Chem 2018; 163:763-778. [PMID: 30576906 DOI: 10.1016/j.ejmech.2018.11.045] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 11/16/2018] [Accepted: 11/19/2018] [Indexed: 11/17/2022]
Abstract
The A2B adenosine receptor is a G protein-coupled receptor that belongs to the four member family of adenosine receptors: A1, A2A, A2B, A3. While adenosine-mediated A2B receptor signaling attenuates acute inflammation, facilitates tissue adaptation to hypoxia, and induces increased ischemia tolerance under conditions of an acute insult, persistently elevated adenosine levels and A2B receptor signaling are characteristics of a number of chronic disease states. In this report we describe the discovery of certain thienouracils (thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones) as antagonists of the A2B adenosine receptor by high-throughput screening from our corporate substance collection. The structure optimization of the initial screening hits led to BAY-545, an A2B receptor antagonist that was suitable for in vivo testing. The structure optimization work, SAR that was derived from there, as well as the properties of BAY-545 are also described. In vivo efficacy of BAY-545 was demonstrated in two models of lung fibrosis and data is presented.
Collapse
Affiliation(s)
- Michael Härter
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany.
| | - Bernd Kalthof
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Martina Delbeck
- Preclinical Research, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Klemens Lustig
- Translational Sciences, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Michael Gerisch
- Translational Sciences, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Simone Schulz
- Translational Sciences, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Raimund Kast
- Preclinical Research, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Daniel Meibom
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Niels Lindner
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| |
Collapse
|
10
|
Wu M, Claus P, Meyer J, Scheerer NA, Janssens T, Stampfuss J, Gillijns H, Grah C, Moosmang S, Meibom D, Janssens S. P6416Introducing microvascular dysfunction in a large animal model of ST-elevation myocardial infarction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Wu
- KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium
| | - P Claus
- KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium
| | - J Meyer
- Bayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany
| | - N A Scheerer
- Bayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany
| | | | - J Stampfuss
- Bayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany
| | - H Gillijns
- KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium
| | - C Grah
- Bayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany
| | - S Moosmang
- Bayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany
| | - D Meibom
- Bayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany
| | - S Janssens
- KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium
| |
Collapse
|
11
|
Meibom D, Albrecht-Küpper B, Diedrichs N, Hübsch W, Kast R, Krämer T, Krenz U, Lerchen HG, Mittendorf J, Nell PG, Süssmeier F, Vakalopoulos A, Zimmermann K. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1Receptor Agonist for the Chronic Treatment of Heart Diseases. ChemMedChem 2017; 12:728-737. [DOI: 10.1002/cmdc.201700151] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Revised: 04/12/2017] [Indexed: 11/09/2022]
Affiliation(s)
- Daniel Meibom
- Medicinal Chemistry Wuppertal; Bayer AG; 42113 Wuppertal Germany
| | | | - Nicole Diedrichs
- Project Management, Development; Bayer AG; 42113 Wuppertal Germany
| | - Walter Hübsch
- Medicinal Chemistry Wuppertal; Bayer AG; 42113 Wuppertal Germany
| | - Raimund Kast
- Department of Cardiology Research Wuppertal; Bayer AG; 42113 Wuppertal Germany
| | - Thomas Krämer
- Medicinal Chemistry Wuppertal; Bayer AG; 42113 Wuppertal Germany
| | - Ursula Krenz
- Medicinal Chemistry Wuppertal; Bayer AG; 42113 Wuppertal Germany
| | | | | | - Peter G. Nell
- Medicinal Chemistry Wuppertal; Bayer AG; 42113 Wuppertal Germany
| | - Frank Süssmeier
- Medicinal Chemistry Wuppertal; Bayer AG; 42113 Wuppertal Germany
| | | | | |
Collapse
|
12
|
von Nussbaum F, Li VM, Meibom D, Anlauf S, Bechem M, Delbeck M, Gerisch M, Harrenga A, Karthaus D, Lang D, Lustig K, Mittendorf J, Schäfer M, Schäfer S, Schamberger J. Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model. ChemMedChem 2015; 11:199-206. [PMID: 26333652 DOI: 10.1002/cmdc.201500269] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2015] [Indexed: 12/20/2022]
Abstract
Human neutrophil elastase (HNE) is a key driver of inflammation in many cardiopulmonary and systemic inflammatory and autoimmune conditions. Overshooting high HNE activity is the consequence of a disrupted protease-antiprotease balance. Accordingly, there has been an intensive search for potent and selective HNE inhibitors with suitable pharmacokinetics that would allowing oral administration in patients. Based on the chemical probe BAY-678 and the clinical candidate BAY 85-8501 we explored further ring topologies along the equator of the parent pyrimidinone lead series. Novel ring systems were annulated in the east, yielding imidazolo-, triazolo-, and tetrazolopyrimidines in order to ensure additional inhibitor-HNE contacts beyond the S1 and the S2 pocket of HNE. The western annulation of pyridazines led to the polar pyrimidopyridazine BAY-8040, which combines excellent potency and selectivity with a promising pharmacokinetic profile. In vivo efficacy with regard to decreasing cardiac remodeling and amelioration of cardiac function was shown in a monocrotaline-induced rat model for pulmonary arterial hypertension. This demonstrated in vivo proof of concept in animals.
Collapse
Affiliation(s)
- Franz von Nussbaum
- Medicinal Chemistry Berlin, Bayer HealthCare AG, 13353, Berlin, Germany.
| | - Volkhart M Li
- Lead Discovery Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany.
| | - Daniel Meibom
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany.
| | - Sonja Anlauf
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Martin Bechem
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Martina Delbeck
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Michael Gerisch
- DMPK Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Axel Harrenga
- Lead Discovery, Structural Biology Berlin, Bayer HealthCare AG, 13353, Berlin, Germany
| | - Dagmar Karthaus
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Dieter Lang
- DMPK Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Klemens Lustig
- DMPK Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Joachim Mittendorf
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Martina Schäfer
- Lead Discovery, Structural Biology Berlin, Bayer HealthCare AG, 13353, Berlin, Germany
| | - Stefan Schäfer
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| | - Jens Schamberger
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096, Wuppertal, Germany
| |
Collapse
|
13
|
von Nussbaum F, Li VMJ, Allerheiligen S, Anlauf S, Bärfacker L, Bechem M, Delbeck M, Fitzgerald MF, Gerisch M, Gielen-Haertwig H, Haning H, Karthaus D, Lang D, Lustig K, Meibom D, Mittendorf J, Rosentreter U, Schäfer M, Schäfer S, Schamberger J, Telan LA, Tersteegen A. Cover Picture: Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases (ChemMedChem 7/2015). ChemMedChem 2015. [DOI: 10.1002/cmdc.201590019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
14
|
von Nussbaum F, Li VMJ, Allerheiligen S, Anlauf S, Bärfacker L, Bechem M, Delbeck M, Fitzgerald MF, Gerisch M, Gielen-Haertwig H, Haning H, Karthaus D, Lang D, Lustig K, Meibom D, Mittendorf J, Rosentreter U, Schäfer M, Schäfer S, Schamberger J, Telan LA, Tersteegen A. Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem 2015; 10:1163-73. [PMID: 26083237 PMCID: PMC4515084 DOI: 10.1002/cmdc.201500131] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Indexed: 12/01/2022]
Abstract
Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors should reestablish the protease-anti-protease balance. By means of medicinal chemistry a novel dihydropyrimidinone lead-structure class was identified. Further chemical optimization yielded orally active compounds with favorable pharmacokinetics such as the chemical probe BAY-678. While maintaining outstanding target selectivity, picomolar potency was achieved by locking the bioactive conformation of these inhibitors with a strategically positioned methyl sulfone substituent. An induced-fit binding mode allowed tight interactions with the S2 and S1 pockets of HNE. BAY 85-8501 ((4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile) was shown to be efficacious in a rodent animal model related to ALI. BAY 85-8501 is currently being tested in clinical studies for the treatment of pulmonary diseases.
Collapse
Affiliation(s)
- Franz von Nussbaum
- Medicinal Chemistry Berlin, Bayer HealthCare AG, 13353 Berlin (Germany).
| | - Volkhart M-J Li
- Lead Discovery Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany).
| | - Swen Allerheiligen
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Sonja Anlauf
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Lars Bärfacker
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Martin Bechem
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Martina Delbeck
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | | | - Michael Gerisch
- DMPK Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | | | - Helmut Haning
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Dagmar Karthaus
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Dieter Lang
- DMPK Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Klemens Lustig
- DMPK Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Daniel Meibom
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Joachim Mittendorf
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Ulrich Rosentreter
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Martina Schäfer
- Lead Discovery, Structural Biology Berlin, Bayer HealthCare AG, 13353 Berlin (Germany)
| | - Stefan Schäfer
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Jens Schamberger
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Leila A Telan
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Adrian Tersteegen
- Lead Discovery Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| |
Collapse
|
15
|
Meibom D, Bauser M, Meier H, Schneider D, Svenstrup N, Haebich D. Diversity-Oriented Synthesis of Substituted Pyrazolo[4,3-d][1,2,3]triazin-4-ones. HETEROCYCLES 2009. [DOI: 10.3987/com-08-11482] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
16
|
|
17
|
|